Update on NSAID Use:.

Slides:

Advertisements

Similar presentations

CLINICAL QUESTION By: Resident Name. 25 y/o male w/ hx of ___, ____, and ____, who presented w/ _______ found to have ________ admitted for ______ and.

Advertisements

Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.

Estimate of Certainty (Precision) of Treatment Effect Level of evidence of B or C does not imply that recommendation is weak. LEVEL A Multiple populations.

Advisory Committee Presentation on Vioxx (Rofecoxib) Discussion on the meta analyses for cardiovascular risk assessment Qian Li, Sc. D.

Copyleft Clinical Trial Results. You Must Redistribute Slides The American College of Cardiology Foundation / American Heart Association Clopidogrel Recommendations.

What about VIOXX?. Adenomatous Polyp Prevention on Vioxx (APPROVe) Vioxx (rofecoxib) versus Placebo Basic Clinical Trial Objective: Assess whether Vioxx.

Hot Topic Presentation Lars Halford, GP ST3 March 2010

Drug Regulation in Controversy: Vioxx November 10, 2004 Sandra L. Kweder, M.D. Deputy Director, Office of New Drugs Center for Drug Evaluation and Research.

Addressing the Challenges in Primary and Secondary Stroke Prevention

Pravastatin in Elderly Individuals at Risk of Vascular Disease

What is the likely mechanism by which HDL-C reduces coronary heart disease?

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.

Emerging Concepts in Heart Failure

Selection of NSAIDs for Osteoarthritis

Optimizing Statin Therapy

Current Dyslipidemia Management Guidelines Residual Risk.

Optimizing Therapy for Osteoarthritis

Achieving Long-Term Protection Post-MI

Heart Rate, HF Admissions, and Readmissions

Current Controversies in Multiple Sclerosis Management

A New Era for NOACs:.

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Select Topics in Cardiovascular Medicine

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

Through Thick and Thin.

NSAIDs: Risk of acute MI compared with remote use

Drug used within 3 months of index date Adjusted odds ratio* p

Cost Effectiveness and Optimal Outcomes in HF

Understanding Statin Metabolism

Oral Anticoagulants in AFa,b A Brief History.

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

Clinical Application of New CV Outcomes Data

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Diabetes Increases Risk of CVD

Assessing the State of Statin Therapy

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

A Journal Club on Lipid Management:

Tackling CV Risk in T2DM.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Expert Insights on Complex Clinical Cases of Edema

OTC NSAID Use in Patients With OA and CV Disease

Risk Stratification in CAD and PAD

Oral Anticoagulation in AF

Remote Patient Management:

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

LEADER One Year On.

Using Heart Rate as a Biomarker in Clinical Practice.

Updates in Heart Failure:

Revisiting the Pharmacoeconomics of HF

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

CAD/PAD in Primary Care

Number of patients who received at least one prescription for a COX-2 inhibitor or NSAID after hospital discharge Drug Patients % of study cohort Rofecoxib.

Managing Pulmonary Embolism Posthospital Discharge

Iron Deficiency in Heart Failure

Challenges in LA SCCHN.

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Live on PAH: Breathing Life Into Patients With PAH

Treating Osteoarthritis

2015 EASD In Review: CV Risk management in t2dm

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Emerging Advances in Reducing Renal Complications of T2D

Lipids, the Heart, and the Kidney

Top Tips in Evidence-Based Care for HFrEF

Expert Perspectives.

Key Data on Improving Outcomes in HF Patients

Fresh perspectives ON BASAL Insulins in diabetes care

Presentation transcript:

Update on NSAID Use:

NSAIDS: The Heart of the Controversy

How NSAIDs Work

NSAIDs: COX-1 and COX-2 Effects

NSAID-Aspirin Interaction Competitive Inhibition of COX in the Platelet?

CV Risks: an Ongoing Concern

Historical Data on CV Risks of NSAIDs

Mechanism of NSAID-Related Cardiotoxicity In Vitro Effects

NSAIDs and HF Clinical Effects

Revisiting the Question of Direct Cardiotoxicity of NSAIDs

The Link Between HF and Specific NSAIDs

Dose-Related AEs of Meloxicam

Meta-Analysis of CV Risk With NSAIDs

Meta-Analysis of CV Risk With NSAIDs Rofecoxib Stands Out

PRECISION Trial Design

PRECISION: Top-Line Results

PRECISION: Limitations of Methodology

PRECISION: Limitations of Study Population

PRECISION: No Information About NSAID-Aspirin Interaction

PRECISION: Concerns About Pharmacoequivalence

Does PRECISION Help Us Take Care of Patients With Excess CV Risk?

Does PRECISION Help Us Take Care of Patients With Excess CV Risk Does PRECISION Help Us Take Care of Patients With Excess CV Risk? (cont)

Take-Home Messages

Summary